Fig. 4From: Inflammatory markers predict survival in patients with postoperative urothelial carcinoma receiving tislelizumab (PD-1 inhibitor) adjuvant therapyComparison of DFS(e) and OS(f) curves between patients with different groups (MLR<0.31, MLR>0.31). e: Patients with low MLR had longer DFS [HR 1.067 (95% CI, 0.474, 1.884); p = 0.049]; f: Patients with low MLR had longer OS [HR 4.289(95% CI, 1.456, 3.638); p < 0.01]Back to article page